Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation

Lung Cancer

Volumn 90, Issue 3, 2015, Pages 369-374

  Jorge, Susan E ^a   Schulman, Sol ^a   Freed, Jason A ^a   VanderLaan, Paul A ^a   Rangachari, Deepa ^a   Kobayashi, Susumu S ^a   Huberman, Mark S ^a   Costa, Daniel B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adenocarcinoma; ALK; Amplification; Ceritinib; Crizotinib; Exon 14; Lung cancer; MET; Mutation; PIK3CA; ROS1

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CERITINIB; CRIZOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC ALPHA; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN;

ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; EXON SKIPPING; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; MAJOR CLINICAL STUDY; MET GENE; ONCOGENE; ONCOGENE C ROS 1; PRIORITY JOURNAL; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR GENE; ADENOCARCINOMA; ALTERNATIVE RNA SPLICING; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; GENETICS; GENOMIC INSTABILITY; GENOTYPE; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; PHOSPHORYLATION; TREATMENT OUTCOME; TUMOR CELL LINE; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; GENE AMPLIFICATION; GENOMIC INSTABILITY; GENOTYPE; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84949214473     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.10.028     Document Type: Article

References (25)

1. Jorge S.E., Kobayashi S.S., Costa D.B. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz. J. Med. Biol. Res. 2014, 47:929-939.
2. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
3. Camidge D.R., Bang Y.J., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012, 13:1011-1019.
4. Shaw A.T., Kim D.W., Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368:2385-2394.
5. Solomon B.J., Mok T., Kim D.W., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014, 371:2167-2177.
6. Christensen J.G., Zou H.Y., Arango M.E., et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 2007, 6:3314-3322.
7. Yasuda H., Figueiredo-Pontes L.L., Kobayashi S., Costa D.B. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J. Thorac. Oncol. 2012, 7:1086-1090.
8. Gerber D.E., Gandhi L., Costa D.B. Management and future directions in non-small cell lung cancer with known activating mutations. Am. Soc. Clin. Oncol. Educ. Book 2014, e353-e365.
9. Camidge D.R., Ou S.H., Shapiro G., et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2014, 32. (suppl; abstr 8001).
10. Shaw A.T., Ou S.H., Bang Y.J., et al. Crizotinib in ROS1- rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014, 371:1963-1971.
11. Mazieres J., Zalcman G., Crino L., et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1Cohort. J. Clin. Oncol. 2015, 33:992-999.
12. Ou S.H., Kwak E.L., Siwak-Tapp C., et al. Activity of crizotinib (PF02341066), a dual mesenchymal- epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 2011, 6:942-946.
13. Collisson E.A., Campbell J.D., Brooks A.N. Cancer genome atlas research network: comprehensive molecular profiling of lung adenocarcinoma. Nature 2014, 511:543-550.
14. Kris M.G., Johnson B.E., Berry L.D., et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014, 311:1998-2006.
15. Jenkins R.W., Oxnard G.R., Elkin S., Sullivan E.K., Carter J.L., Barbie D.A. Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. Clin. Lung Cancer 2015, 16(5):e101-e104.
16. Paik P.K., Drilon A., Yu H., et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015, 5(8):842-849.
17. Frampton G.M., Fichtenholtz A., Otto G.A., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 2013, 31:1023-1031.
18. Zheng Z., Liebers M., Zhelyazkova B., et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat. Med. 2014, 20:1479-1484.
19. VanderLaan P.A., Yamaguchi N., Folch E., et al. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer 2014, 84:39-44.
20. Yasuda H., Park E., Yun C.H., et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci. Transl. Med. 2013, 5. 216ra177.
21. Kubo T., Yamamoto H., Lockwood W.W., et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int. J. Cancer 2009, 124:1778-1784.
22. Kong-Beltran M., Seshagiri S., Zha J., et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006, 66:283-289.
23. Liu X., Jia Y., Stoopler M.B., et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J. Clin. Oncol. 2015, (in press) (Jul 27. pii: JCO.2015.62.0674).
24. Le X., Freed J.A., VanderLaan P.A., et al. Detection of crizotinib-sensitive lung adenocarcinomas with METALK and ROS1genomic alterations via comprehensive genomic profiling. Clin. Lung Cancer 2015, 16(5):e105-e109.
25. Yamaguchi N., Lucena-Araujo A.R., Nakayama S., et al. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer 2014, 83:37-43.